CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.3% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2026 Feb 23, 03:06

Brokerages Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Price Target at $140.10 - Stock Observer

BioNTech SE
Webhose 2026 Feb 22, 02:58

Raiffeisen Bank International AG Has $1.57 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX - Daily Political

BioNTech SE
Webhose 2026 Feb 20, 12:55

BioNTech fires shots at Moderna's next-generation vaccine | Americas | Life Sciences Intellectual Property Review

BioNTech SE
Webhose 2026 Feb 20, 10:59

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

BioNTech SE
Webhose 2026 Feb 20, 02:46

BioNTech Takes Legal Action Against Moderna for COVID Vaccine Patent Infringement, ETPharma

BioNTech SE
Webhose 2026 Feb 19, 13:18

FDA Fast Track Win And New HR Chief Might Change The Case For Investing In BioNTech (BNTX)

BioNTech SE
Webhose 2026 Feb 19, 08:43

BioNTech SE (BNTX) Rallying on Solid Oncology Strategy

BioNTech SE
Webhose 2026 Feb 18, 09:57

Aberdeen Group plc Has $28.79 Million Stock Position in BioNTech SE Sponsored ADR $BNTX

BioNTech SE
Webhose 2026 Feb 18, 00:00

Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC

BioNTech SE
Webhose 2026 Feb 17, 00:00

BioNtech Stock Forecast 2026-2030 | Future Outlook | Capital.com

BioNTech SE
Webhose 2026 Feb 13, 09:18

Bristol-Myers Squibb Resets Pipeline With RNA Deals And Cost Focus

BioNTech SE
Webhose 2026 Feb 06, 19:18

BioNTech Hire Signals People Focus As Oncology Plans And Valuation Attract Attention

BioNTech SE
Webhose 2026 Feb 05, 06:58

BioNTech (NASDAQ:BNTX) Cut to Market Perform at Leerink Partners - Zolmax

BioNTech SE
Webhose 2026 Feb 05, 00:00

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy

BioNTech SE
Webhose 2026 Feb 03, 19:27

BioNTech Adds Chief People Officer To Support Oncology Growth Plans

BioNTech SE
Webhose 2026 Feb 02, 13:15

Assessing BioNTech (BNTX) Valuation After Goldman Sachs Buy Upgrade And Oncology Growth Focus

BioNTech SE
Webhose 2026 Feb 02, 12:43

BioNTech (NASDAQ:BNTX) Rating Lowered to Market Perform at Leerink Partners

BioNTech SE
Webhose 2026 Feb 02, 00:00

Africa's deep tech boom rests on a fragile research ecosystem

BioNTech SE
Webhose 2026 Jan 31, 13:25

Lingohr Asset Management GmbH Acquires 40,821 Shares of BioNTech SE Sponsored ADR $BNTX

BioNTech SE
Webhose 2026 Jan 31, 12:32

Privium Fund Management B.V. Acquires 8,013 Shares of BioNTech SE Sponsored ADR $BNTX

BioNTech SE
Webhose 2026 Jan 31, 05:25

BioNTech SE Sponsored ADR $BNTX Shares Purchased by Lingohr Asset Management GmbH - Daily Political

BioNTech SE
Webhose 2026 Jan 31, 01:56

BioNTech (NASDAQ:BNTX) vs. uniQure (NASDAQ:QURE) Critical Analysis - Daily Political

BioNTech SE
Webhose 2026 Jan 30, 07:07

Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline

BioNTech SE
Webhose 2026 Jan 30, 05:33

BioNTech Advances Oncology Focus With BNT324 Trial And Leadership Shift

BioNTech SE
Webhose 2026 Jan 29, 05:00

Appointments and advancements for Jan. 29, 2026 | BioWorld

BioNTech SE
Webhose 2026 Jan 28, 14:13

BioNTech SE (BNTX): A Bull Case Theory

BioNTech SE
Webhose 2026 Jan 28, 10:26

BioNTech SE's (NASDAQ:BNTX) Price Is Right But Growth Is Lacking After Shares Rocket 26% - Simply Wall St News

BioNTech SE
Webhose 2026 Jan 27, 02:25

Is BioNTech (BNTX) Pricing Reflect Its mRNA Pipeline Potential After Recent Share Price Gains

BioNTech SE
Webhose 2026 Jan 26, 14:00

BioNTech Shares Surge in 2026 as Analysts See Further Upside

BioNTech SE
Webhose 2026 Jan 26, 13:00

Lbp Am Sa Acquires 47,859 Shares of BioNTech SE Sponsored ADR $BNTX - Zolmax

BioNTech SE
Webhose 2026 Jan 26, 12:26

BioNTech SE Sponsored ADR $BNTX Holdings Boosted by Lbp Am Sa

BioNTech SE
Webhose 2026 Jan 26, 07:39

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

BioNTech SE

BioNTech news

Latest news

Show more

Info

Spread

1.1855

Spread (%)

1.0745 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Wednesday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

27584815104

Shares Outstanding

250930737

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-2.83

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Trustpilot